2018 Press Releases

Keyword Search
 
2018 | 2017 | 2016 | 2015 | 2014
DateTitle 
08/06/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., Aug. 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on August 1, 2018 it issued inducement awards to two new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides... 
Printer Friendly Version
08/02/18T2 Biosystems Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Quarterly Product Revenue Up 71% Year-Over-Year Launched the Recently FDA Cleared T2Bacteria Panel, the Flagship Product in the T2Direct Diagnostics Portfolio Reiterates 2018 Financial Guidance, Including Increase to Lower End of Revenue Guidance Range LEXINGTON, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced to... 
Printer Friendly Version
07/24/18T2 Biosystems to Participate in Two Upcoming Conferences
LEXINGTON, Mass., July 24, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to participate in two upcoming investor conferences. The first conference is the 3rd Annual Needham MedTech 1x1 Conference, which is being held August 7 in Boston. This conferen... 
Printer Friendly Version
07/20/18T2 Biosystems Announces 2018 Second Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., July 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 second quarter financial and operational results after the market closes on Thursday, August 2, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Easte... 
Printer Friendly Version
07/09/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., July 09, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on July 2, 2018 it issued inducement awards to three new employees. These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides fo... 
Printer Friendly Version
06/25/18T2 Biosystems Added to the Russell 3000® Index
LEXINGTON, Mass., June 25, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today that it has been added to the broad-market Russell 3000® Index. The addition occurred at the conclusion of trading on June 22, 2018 and is effective after the US market opens on June 25, 2018. Annual Russell US Indexes reconstitution captures the 4,000 largest US stocks as of May... 
Printer Friendly Version
06/13/18Late-Breaking Data and Clinician Reviews on Now FDA-cleared T2Bacteria Panel Underscore Sepsis Prevention Opportunities at ASM Microbe 2018
LEXINGTON, Mass., June 13, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development of innovative diagnostic products for critical unmet needs in healthcare, announced today late-breaker posters and data presented at the American Society for Microbiology (ASM) Microbe conference on June 7-11 that demonstrate the T2Bacteria® Panel’s accuracy and speed, which may enable more rapid treatment of patients with bloodstream infections in order to prevent sepsi... 
Printer Friendly Version
06/06/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., June 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on June 4, 2018 it issued inducement awards to three new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides ... 
Printer Friendly Version
06/05/18T2 Biosystems Announces Closing of Public Offering of Common Stock
LEXINGTON, Mass., June 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the closing of its underwritten public offering of 7,015,000 shares of common stock, including 915,000 shares of common stock pursuant to the underwriters’ exercise in full of their option to purchase additional shares, at a public offering price of $7.50 per share, before underwriting discounts, for gross proceeds of approximately $52.6 million. All of the shares of common stock sold in the o... 
Printer Friendly Version
06/01/18T2 Biosystems to Present at the Jefferies 2018 Global Healthcare Conference
LEXINGTON, Mass., June 01, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, announced today that John McDonough, president and chief executive officer, is scheduled to present at the Jefferies 2018 Global Healthcare Conference. The conference is being held June 5-8 at the Grand Hyatt Hotel in New York. Mr. McDonough is scheduled to present on Tuesd... 
Printer Friendly Version
05/31/18T2 Biosystems Announces Pricing of Public Offering of Common Stock
LEXINGTON, Mass., May 31, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) today announced the pricing of an underwritten registered public offering of 6,100,000 shares of common stock at a public offering price of $7.50 per share, before underwriting discounts, for gross proceeds of $45,750,000. T2 Biosystems has granted the underwriters a 30-day option to purchase up to an additional 915,000 shares of common stock at the public offering price, less the underwriting discount.  All o... 
Printer Friendly Version
05/29/18T2 Biosystems Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass., May 29, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO), an emerging leader in the development and commercialization of innovative diagnostic products for critical unmet needs in healthcare, today announced that it is commencing an underwritten registered public offering of 5,650,000 shares of its common stock. T2 Biosystems also intends to grant the underwriters a 30-day option to purchase up to an additional 847,500 shares of its common stock.  All of the shares ... 
Printer Friendly Version
05/29/18T2 Biosystems Receives FDA Clearance to Market T2Bacteria Panel for Detection of Sepsis-Causing Pathogens
First FDA-cleared test to identify sepsis-causing bacteria direct from whole blood Cuts time to diagnosis from days to hours, allowing greater certainty and new protocols for deadly infections in hospital settingCompany to host conference call to discuss T2Bacteria and provide financial guidance at 8:30 a.m. ET on Tuesday, May 29, 2018 LEXINGTON, Mass.,May 29, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative d... 
Printer Friendly Version
05/08/18T2 Biosystems Reports First Quarter 2018 Financial Results and Provides Corporate Update
Quarterly Product Revenue Up 66% Year-Over-Year On Track for Potential FDA Clearance of T2Bacteria Panel in the Second Quarter 2018 LEXINGTON, Mass., May 08, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the first quarter ended March 31, 2018.   First Quarter Business and Fi... 
Printer Friendly Version
05/03/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on May 1, 2018 it issued inducement awards to four new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides fo... 
Printer Friendly Version
04/30/18T2 Biosystems Announces 2018 First Quarter Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., April 30, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2018 first quarter financial and operational results after the market closes on Tuesday, May 8, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30 p.m. Eastern T... 
Printer Friendly Version
04/04/18T2 Biosystems Reports Granting of Inducement Awards
LEXINGTON, Mass., April 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that on April 2, 2018 it issued inducement awards to five new employees.    These awards were made under T2 Biosystems’ Inducement Award Plan (the "Inducement Plan"), which was adopted by the company’s Board of Directors on March 1, 2018 and provides... 
Printer Friendly Version
03/28/18Multiple New Studies Demonstrate T2 Biosystems’ Diagnostics Improve Detection of Sepsis Causing Pathogens Over Blood Culture-based Diagnostics
U.S. and EU studies demonstrate that T2Dx diagnostics enable getting patients on the right therapy faster, improving outcomes, enhancing stewardship, and reducing the cost of care LEXINGTON, Mass., March 28, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products, announces the publication of four new, peer-reviewed studies that demonstrate the clinical and performance advantages of the T... 
Printer Friendly Version
03/19/18T2 Biosystems to Present at the 17th Annual Needham Healthcare Conference
LEXINGTON, Mass., March 19, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer is scheduled to present at the 17th Annual Needham Healthcare Conference.  The conference is being held March 27-28 at the Westin Grand Central Hotel in New York. The Company is scheduled to ... 
Printer Friendly Version
03/07/18T2 Biosystems Reports Granting of Inducement Award
LEXINGTON, Mass., March 07, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it issued an inducement award to John Sprague, the Company’s recently appointed Chief Financial Officer, in accordance with the terms of Mr. Sprague’s employment offer letter. The award was made on March 1, 2018 under T2 Biosystems’ Inducement A... 
Printer Friendly Version
03/06/18T2 Biosystems Reports Fourth Quarter and Full-Year 2017 Financial Results and Business Update
Quarterly Product Revenue Up 125% Year-Over-Year and 76% Over the Prior Quarter LEXINGTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today operating highlights and financial results for the fourth quarter and year ended December 31, 2017.   Fourth Quarter Business and Financial Performance Highlights: ... 
Printer Friendly Version
03/06/18T2 Biosystems Awarded Up To $2 Million by CARB-X to Support Development of New Tests on the T2Dx Instrument for Drug-Resistant Bacteria
New tests aim to expand T2Dx Instrument product line by detecting 20 additional bacterial species and resistance targets that could empower doctors to rapidly treat more patients with targeted therapyLEXINGTON, Mass., March 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, announced today that it has been awarded a grant of up to $2 milli... 
Printer Friendly Version
02/20/18T2 Biosystems Announces 2017 Fourth Quarter and Full-Year Financial and Operational Results Release and Conference Call Date
LEXINGTON, Mass., Feb. 20, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) an emerging leader in the development and commercialization of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that it will release its 2017 fourth quarter and full-year financial and operational results after the market closes on Tuesday, March 6, 2018. In conjunction with the release, the Company will host a conference call with the investment community at 4:30... 
Printer Friendly Version
02/09/18Two New Studies Demonstrate T2Candida’s Advantages over Current Diagnostic Testing
Studies demonstrate T2Candida identifies infections missed by blood culture and the opportunity for faster targeted therapy LEXINGTON, Mass., Feb. 09, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, is announcing the release of two new peer-reviewed publications that demonstrate the superior performance of the T2Candida® Panel over blood culture and the capability of the T... 
Printer Friendly Version
02/06/18T2 Biosystems to Present at the 7th Annual Leerink Partners Global Healthcare Conference
LEXINGTON, Mass., Feb. 06, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John McDonough, president and chief executive officer is scheduled to present at the 7th Annual Leerink Partners Global Healthcare Conference.  The conference is being held February 14-15 at the Lotte New York Palace Hotel in New York.   The Company is scheduled to present on T... 
Printer Friendly Version
02/05/18T2 Biosystems Announces CFO Transition
LEXINGTON, Mass., Feb. 05, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO) a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced that John Sprague has been named chief financial officer. Mr. Sprague is a highly accomplished financial executive who brings an extensive array of financial experience to T2 Biosystems, including a demonstrated success and leadership in building out companies during high-growth per... 
Printer Friendly Version
01/04/18T2 Biosystems Announces Preliminary Fourth Quarter 2017 Financial Results and Provides Update on T2Bacteria Panel
FDA Clearance of T2Bacteria® Panel remains on track for first quarter 2018 Total revenue expected to exceed the high end of guidance LEXINGTON, Mass., Jan. 04, 2018 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development of innovative medical diagnostic products for critical unmet needs in healthcare, today announced preliminary revenue and business results for the three months ended December 31, 2017 and provided an update on its 510(k) filing with the U.S. Food... 
Printer Friendly Version